Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data - Vale, C L; Burdett, S; Rydzewska, L HM (The Lancet Oncology, 2016)
. doi:10.1016/S1470-2045(15)00489-1